Dietze, Kenneth A. https://orcid.org/0000-0002-8069-0210
Nguyen, Kiet
Pathni, Aashli
Fazekas, Frank
Sun, Wenxiang
Rosati, Ethan
Baker, Jillian M. https://orcid.org/0000-0001-5935-8339
Galeana Figueroa, Maday
Gebru, Etse
Yamoah, Daniel
Mulatu, Rediet
Wang, Alexander
Rapoport, Aaron P.
Lum, David H. https://orcid.org/0000-0002-0159-8724
Fan, Xiaoxuan https://orcid.org/0000-0003-0501-771X
Radhakrishnan, Sabarinath V.
Atanackovic, Djordje https://orcid.org/0000-0003-4747-488X
Upadhyaya, Arpita
Luetkens, Tim https://orcid.org/0000-0002-7085-9027
Funding for this research was provided by:
Maryland Department of Health and Mental Hygiene (CH-649-CRF)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R21CA297125)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA042014)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA042014)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA042014)
American Cancer Society (DBG-25-1434942-01-ET)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI095190)
U.S. Department of Health & Human Services | National Institutes of Health (GM145313)
Article History
Received: 30 July 2024
Revised: 30 January 2026
Accepted: 23 February 2026
First Online: 22 April 2026
Competing interests
: K.A.D. and T.L. are inventors on patent application number PCT/US24/53867 describing therapeutic targeting of tumor escape by CMT. T.L. received a salary from AbbVie. The other authors are not declaring any conflicts of interest.